A cocktail nanovaccine targeting key entry glycoproteins elicits high neutralizing antibody levels against EBV infection
Abstract Epstein-Barr virus (EBV) infects more than 95% of adults worldwide and is closely associated with various malignancies. Considering the complex life cycle of EBV, developing vaccines targeting key entry glycoproteins to elicit robust and durable adaptive immune responses may provide better...
| প্রধান লেখক: | , , , , , , , , , , , , , , , , , , |
|---|---|
| বিন্যাস: | প্রবন্ধ |
| ভাষা: | English |
| প্রকাশিত: |
Nature Portfolio
2024-06-01
|
| মালা: | Nature Communications |
| অনলাইন ব্যবহার করুন: | https://doi.org/10.1038/s41467-024-49546-w |